At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 26 enrolled
Drug / intervention
Solifenacin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Compare the Cognitive Effect of Solifenacin 5mg Once-daily and Oxybutynin 5mg Twice-daily After Chronic Dosing Versus Placebo in Subjects 75 Years and Over With Mild Cognitive Impairment - A Double-blind, Randomized, Multi-center Study
In Brief
A Phase 4 clinical trial evaluating Solifenacin, Oxybutynin, and 1 other intervention for Cognition. Completed, enrolled 26 participants across 3 sites.
Detailed Summary
The purpose is to compare solifenacin and oxybutynin with an inactive tablet and assess any potential effects on mental ability.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCognition
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2010
First PostedMay 2010
Primary CompletionDec 2010
TodayJul 2026
First PostedMay 19, 2010
Enrollment StartApr 1, 2010
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 16.1 years ago
Interventions
Solifenacindrug
tablet
Oxybutynindrug
capsule
Placebodrug
tablet